Zai Lab (ZLAB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Voting matters and shareholder proposals
Nine director nominees are up for re-election to serve until the 2027 annual general meeting, subject to earlier resignation or removal.
Appointment of KPMG LLP and KPMG as independent auditors for the year ending December 31, 2026, is up for approval.
Board authority to fix auditor compensation for 2026 is subject to shareholder approval.
Advisory vote on executive compensation for named executive officers is included.
Proposals include mandates to issue up to 10% new shares and to repurchase up to 10% of issued shares until the 2027 meeting.
Board of directors and corporate governance
Nine individuals are nominated for re-election to the board, with each recommended by the board.
Executive compensation and say-on-pay
Advisory approval is sought for the compensation of named executive officers as disclosed in the proxy statement.
Latest events from Zai Lab
- Proxy covers director elections, auditor appointments, compensation, share mandates, and ESG strategy.ZLAB
Proxy filing28 Apr 2026 - Strong intracranial and systemic efficacy with favorable safety in SCLC and neuroendocrine tumors.ZLAB
Study update21 Apr 2026 - Shareholders will vote on director re-elections, auditor appointments, compensation, and share mandates.ZLAB
Proxy filing17 Apr 2026 - 2025 revenue up 15% to $460.2M, net loss narrowed, and pipeline advances set up 2026 milestones.ZLAB
Q4 202526 Feb 2026 - Global pipeline advances with DLL3 ADC phase III, new ADCs, and immunotherapies entering clinic.ZLAB
Citi’s 2026 Virtual Oncology Leadership Summit23 Feb 2026 - Strong VYVGART launch, pipeline expansion, and solid cash position drive growth and profitability.ZLAB
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - Q2 2024 revenue up 45% to $100.1M, net loss narrows, VYVGART guidance raised above $80M.ZLAB
Q2 20242 Feb 2026 - Targeting 50% annual sales growth and profitability by Q4 2025, fueled by new product launches.ZLAB
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - 74% response rate and strong safety in advanced SCLC, supporting rapid global development.ZLAB
Status Update18 Jan 2026